Comorbidity and survival among women with ovarian cancer: Evidence from prospective studies

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Jiao, Yi Sheng ^a   Gong, Ting Ting ^a   Wang, Yong Lai ^a   Wu, Qi Jun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMORBIDITY; CONFIDENCE INTERVAL; FEMALE; HUMAN; META ANALYSIS; MORTALITY; OVARY TUMOR; PROSPECTIVE STUDY; RISK FACTOR;

COMORBIDITY; CONFIDENCE INTERVALS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84934326484     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11720     Document Type: Article

References (40)

1. Ferlay, J. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. (Date of access: 15/ February/2015)
2. DeSantis, C. E. et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 64, 252-71 (2014)
3. Agarwal, R. & Kaye, S. B. Prognostic factors in ovarian cancer: how close are we to a complete picture? Ann Oncol 16, 4-6 (2005)
4. Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376-88 (2014)
5. Valderas, J. M. et al. Defining comorbidity: implications for understanding health and health services. Ann Fam Med 7, 357-63 (2009)
6. Erickson, B. et al. The Charlson Comorbidity Index predicts survival in women with epithelial ovarian cancer independent of surgical debulking status. Gynecol Oncol 134, 428-9 (2014)
7. Sperling, C. et al. Comorbidity is an independent prognostic factor for the survival of ovarian cancer: a Danish register-based cohort study from a clinical database. Gynecol Oncol 129, 97-102 (2013)
8. Tetsche, M. S. et al. The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. Bmc Cancer 8, 31 (2008)
9. Du Bois, A., Rochon, J., Lamparter, C. & Pfisterer, J. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15, 183-91 (2005)
10. OMalley, C. D., Cress, R. D., Campleman, S. L. & Leiserowitz, G. S. Survival of Californian women with epithelial ovarian cancer, 1994-1996: a population-based study. Gynecol Oncol 91, 608-15 (2003)
11. Maas, H. A. et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97, 104-9 (2005)
12. DiSilvestro, P., Peipert, J. F., Hogan, J. W. & Granai, C. O. Prognostic value of clinical variables in ovarian cancer. J Clin Epidemiol 50, 501-5 (1997)
13. Anuradha, S. et al. Survival of Australian women with invasive epithelial ovarian cancer: a population-based study. Med J Aust 201, 283-8 (2014)
14. Jorgensen, T. L., Hallas, J., Friis, S. & Herrstedt, J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer 106, 1353-60 (2012)
15. Fago-Olsen, C. L. et al. Centralized treatment of advanced stages of ovarian cancer improves survival: a nationwide Danish survey. Acta Obstet Gynecol Scand 90, 273-9 (2011)
16. Elit, L. M. et al. Surgical outcomes in women with ovarian cancer. Can J Surg 51, 346-54 (2008)
17. Tetsche, M. S. et al. Comorbidity and ovarian cancer survival in Denmark, 1995-2005: a population-based cohort study. Int J Gynecol Cancer 18, 421-7 (2008)
18. Jorgensen, T. L. et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol 127, 367-74 (2012)
19. Stalberg, K., Svensson, T., Lonn, S. & Kieler, H. The influence of comorbidity on mortality in ovarian cancer patients. Gynecol Oncol 133, 298-303 (2014)
20. Grann, A. F. et al. Comorbidity and survival of Danish ovarian cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol 5, 57-63 (2013)
21. Janssen-Heijnen, M. L. et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 55, 231-40 (2005)
22. Tingulstad, S., Skjeldestad, F. E., Halvorsen, T. B. & Hagen, B. Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101, 885-91 (2003)
23. Robinson, K. M., Christensen, K. B., Ottesen, B. & Krasnik, A. Socio-demographic factors, comorbidity and diagnostic delay among women diagnosed with cervical, endometrial or ovarian cancer. Eur J Cancer Care 20, 653-61 (2011)
24. Rannestad, T. & Skjeldestad, F. E. Co-morbidity and pain sites in long-Term gynecological cancer survivors and women in the general population. Gynecol Oncol 127, 168-71 (2012)
25. Baron, E. et al. Comorbidity and prognosis in serous and papillary serous ovarian cancer. Gynecol Oncol 112, S116-7 (2009)
26. Elit, L., Bondy, S. J., Chen, Z. & Paszat, L. A tale of two time periods: ovarian cancer trends in Ontario. Curr Oncol 14, 57-60 (2007)
27. Monfardini, S. Prescribing anti-cancer drugs in elderly cancer patients. Eur J Cancer 38, 2341-6 (2002)
28. Leontiadis, G. I., Molloy-Bland, M., Moayyedi, P. & Howden, C. W. Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-Analysis. Am J Gastroenterol 108, 331-45, 346 (2013)
29. de Groot, V., Beckerman, H., Lankhorst, G. J. & Bouter, L. M. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 56, 221-9 (2003)
30. Rothman, K. J., Greenland, S. & Lash, T. Validity in epidemiologic studies. In: Modern Epidemiology. 3rd edn, (eds Rothman, K. J. et al.) 128-147. (Lippincott Williams & Wilkins 2008)
31. Stroup, D. F. et al. Meta-Analysis of observational studies in epidemiology: a proposal for reporting. Meta-Analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-12 (2000)
32. Luan, N. N. et al. Breastfeeding and ovarian cancer risk: a meta-Analysis of epidemiologic studies. Am J Clin Nutr 98, 1020-31 (2013)
33. Gong, T. T. et al. Age at menarche and risk of ovarian cancer: a meta-Analysis of epidemiological studies. Int J Cancer 132, 2894-900 (2013)
34. Guan, H. B., Wu, Q. J. & Gong, T. T. Parity and kidney cancer risk: evidence from epidemiologic studies. Cancer Epidemiol Biomarkers Prev 22, 2345-53 (2013)
35. Luan, N. N. et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-Analysis of epidemiological studies. Cancer Causes Control 26, 65-78 (2015)
36. Hamling, J., Lee, P., Weitkunat, R. & Ambuhl, M. Facilitating meta-Analyses by deriving relative effect and precision estimates for alternative comparisons from a set of estimates presented by exposure level or disease category. Stat Med 27, 954-70 (2008)
37. DerSimonian, R. & Laird, N. Meta-Analysis in clinical trials. Control Clin Trials 7, 177-88 (1986)
38. Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-Analysis. Stat Med 21, 1539-58 (2002)
39. Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 315, 629-34 (1997)
40. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-101 (1994)